TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers-Reference-Cited by-同舟云学术

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

Published:2019-02-13 Issue:1 Volume:12 Page:
ISSN:1757-2215
Container-title:Journal of Ovarian Research
language:en
Short-container-title:J Ovarian Res

Author:

Ghisoni Eleonora,Maggiorotto Furio,Borella Fulvio,Mittica Gloria,Genta Sofia,Giannone Gaia,Katsaros Dionyssios,Sciarrillo Alberto,Ferrero Annamaria,Sarotto Ivana,Erriquez Jessica,Di Renzo Maria Flavia,Aglietta Massimo,Valabrega Giorgio

Funder

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13048-019-0492-6.pdf

Reference35 articles.

1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.

2. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.

3. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.

4. Colombo N, Lorusso D, Scollo P. Impact of recurrence of ovarian Cancer on quality of life and outlook for the future. Int J Gynecol Cancer. 2017;27(6):1134–40.

5. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les etudes des cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells;Scientific Reports;2024-06-18

2. TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation;Cancer Biology & Therapy;2024-03-06

3. A Four-Gene Panel for the Prediction of Prognosis and Immune Cell Enrichment in Gliomas;Molecular Biotechnology;2023-08-29

4. Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer;Cancer Medicine;2023-05-15

5. Comprehensive bioinformatics analysis confirms RBMS3 as the central candidate biological target for ovarian cancer;Medical Engineering & Physics;2022-12